Article metrics

  • citations in SCindeks: [2]
  • citations in CrossRef:0
  • citations in Google Scholar:[=>]
  • visits in previous 30 days:11
  • full-text downloads in 30 days:8
article: 7 from 22  
Back back to result list
Vojnosanitetski pregled
2015, vol. 72, iss. 4, pp. 334-341
article language: English
document type: Original Scientific Paper
published on: 02/06/2015
doi: 10.2298/vsp1504334k
End-of-life costs of medical care for advanced stage cancer patients
aMilitary Medical Academy, Centre for Clinical Pharmacology, Belgrade + University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade
bUniversity of Kragujevac, Faculty of Medicine, Department of Pharmacology and Toxicology
cInstitute of Pharmaceutical Medicine/ECPM, University of Basel, Basel, Switzerland

e-mail: sidartagothama@gmail.com

Project

Medical costs structure and budget impact analysis regarding most prevalent and/or most expensive diseases and cost/effectiveness/utility coefficient determination of common medical interventions (MESTD - 175014)

Abstract

Background/Aim. Cancer, one of the leading causes of mortality in the world, imposes a substantial economic bur-den on each society, including Serbia. The aim of this study was to evaluate the major cancer cost drivers in Serbia. Methods. A retrospective, in-depth, bottom-up analysis of two combined databases was performed in order to quantify relevant costs. End-of-life data were obtained from patients with cancer, who deceased within the first year of the established diagnose, including basic demographics, diagnosis, tumour histology, medical resource use and related costs, time and cause of death. All costs were allocated to one of the three categories of cancer health care services: primary care (included home care), hospital outpatient and hospital inpatient care. Results. Exactly 114 patients were analyzed, out of whom a high percent (48.25%) had distant metastases at the moment of establishing the diagnosis. Malignant neoplasms of respiratory and intrathoracic organs were leading causes of morbidity. The average costs per patient were significantly different according to the diagnosis, with the highest (13,114.10 EUR) and the lowest (4.00 EUR) ones observed in the breast cancer and melanoma, respectively. The greatest impact on total costs was observed concerning pharmaceuticals, with 42% of share (monoclonal antibodies amounted to 34% of all medicines and 14% of total costs), followed by oncology medical care (21%), radiation therapy and interventional radiology (11%), surgery (9%), imaging diagnostics (9%) and laboratory costs (8%). Conclusion. Cancer treatment incurs high costs, especially for end-of-life pharmaceutical expenses, ensued from medical personnel tendency to improve such patients' quality of life in spite of nearing the end of life. Reimbursement policy on monoclonal antibodies, in particular at end-stage disease, should rely on cost-effectiveness evidence as well as documented clinical efficiency.
For this article there is a related paper (correction, retraction, or comment) which is available here.

Keywords

References

*** (2010) Health Statistical Yearbook of Republic of Serbia 2010. Belgrade: Institute of Public Health of Serbia
American Cancer Society (2013) Cancer Facts and Figures 2008. Atlanta, Georgia
Arnold, R.G., Kotsanos, J.G. (1999) Panel 3: methodological issues in conducting pharmacoeconomic evaluations--retrospective and claims database studies. Value in health, 2(2): 82-7
Autier, P., Ouakrim, A., Malvezzi, M., Bleiberg, H., Jenkins, M., Boniol, M., et al. (2013) Trends in colorectal cancer mortality and screening activities in European countries. Eur J Cancer, 49(2 Suppl): S299
Earle, C., Neville, B., Landrum, M.B., Ayanian, J., Block, S., Weeks, J. (2004) Trends in the Aggressiveness of Cancer Care Near the End of Life. J Clin Oncol, 22(2); 315-21
Huskamp, H.A., Keating, N.L., Malin, J.L., Zaslavsky, A.M., Weeks, J.C., Earle, C.C., Teno, J.M., Virnig, B.A., Kahn, K.L., He, Y., Ayanian, J.Z. (2009) Discussions with physicians about hospice among patients with metastatic lung cancer. Archives of internal medicine, 169(10): 954-62
Institute of Public Health of Serbia (2012) Health Statistical Yearbook of Republic of Serbia 2011. Belgrade
Institute of Public Health of Serbia (2012) Cancer incidence and mortality in Serbia 2010. Belgrade
Institute of Public Health of Serbia (2013) Health Statistical Yearbook of Republic of Serbia 2012. Belgrade
Jakovljevic, M.B. (2013) Resource allocation strategies in Southeastern European health policy. European journal of health economics, 14(2): 153-9
Jakovljević, M., Ranković, A., Rančić, N., Jovanović, M., Ivanović, M., Gajović, O., Lazić, Z. (2013) Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe-A Retrospective Analysis from Serbia. Value in Health Regional Issues, 2(2): 218-225
Jason, H. Experts debate if the cost of end-of-life cancer care is too high. HemOnc Today, [cited 2009 September 10]. Available from: www.healio.com ›
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D. (2011) Global cancer statistics. CA: a cancer journal for clinicians, 61(2): 69-90
KALÓ, Z., Landa, K., Doležal, T., VOKÓ, Z. (2012) Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. European Journal of Cancer Care, 21(4): 442-449
Leblanc, T.W., Abernethy, A.P. (2013) Defining quality, disseminating evidence, and enforcing guidelines for cancer treatment. virtual mentor, 15(8): 713-7
Luengo-Fernandez, R., Leal, J., Gray, A., Sullivan, R. (2013) Economic burden of cancer across the European Union: a population-based cost analysis. Lancet. Oncology, 14(12): 1165-74
Marsland, T., Robbins, G., Marks, A., Cassell, R., Philips, D.G., King, K. (2010) Reducing cancer costs and improving quality through collaboration with payers: a proposal from the Florida society of clinical oncology. Journal of oncology practice, 6(5): 265-9
Mihajlović, J., Pechlivanoglou, P., Miladinov-Mikov, M., Živković, S., Postma, M.J. (2013) Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer, 13(1): 18
Milijus, D., Zivkovic, S., Bozic, Z. (2012) Cancer incidence and mortality in central Serbia. Belgrade: Institute of Public Health of Serbia 'Dr Milan Jovanović Batut'
Murthy, R., Lakshminarayana, R. (2006) Mental health consequences of war: a brief review of research findings. World psychiatry, 5(1): 25-30
Papathanasiou, K., Gianoulis, C., Tolikas, A., Dovas, D., Koutsos, J., Frag-kedakis, N. (2005) Effect of depleted uranium weapons used in the Balkan war on the incidence of cervical intraepithelial neo-plasia (CIN) and invasive cancer of the cervix in Greece. Clin Exp Obstet Gynecol, 32(1); 58-60
Radovanović, A., Dagović, A., Jakovljević, M. (2011) Economics of cancer related medical care: Worldwide estimates and available domestic evidence. Archive of Oncology, vol. 19, br. 3-4, str. 59-63
Ranković, A., Rančić, N., Jovanović, M., Ivanović, M., Gajović, O., Lazić, Z., Jakovljević, M. (2013) Impact of imaging diagnostics on the budget: Are we spending too much?. Vojnosanitetski pregled, vol. 70, br. 7, str. 709-711
Šipetić, T. (2011) Marketing and consumption of medicinal products for human use in 2010. Belgrade: Agencija za lekove i medicinska sredstva Srbije, (Serbian)
Šipetić, T. (2012) Marketing and consumption of medicinal products for human use in 2011. Belgrade: Agencija za lekove i medicinska sredstva Srbije, (Serbian)
Uyl-de, G.C.A. (2006) Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care. European Journal of Cancer, 42(17): 2862-6
World Health Organization (2008) Global burden of the disease: 2004 update. Geneva, World Health Organization
World Health Organization (2013) World Health Statistics 2013. Geneva
Zweifel, P. (2012) The Grossman model after 40 years. European journal of health economics, 13(6): 677-82